Business Wire

HyperLight Launches 110GHz Intensity Modulator with Record low Vπ, Leveraging Its TFLN Chiplet ™ Platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--HyperLight, creator of the TFLN Chiplet™ platform, today announced the launch of its groundbreaking 110 GHz Low Vπ Intensity Modulator, featuring industry-standard ...
Science Daily

Proton therapy demonstrates advantages in Phase III head and neck cancer trial

According to preliminary data from a multi-institution Phase III trial intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when ...
ascopubs.org

Influence of intensity-modulated radiation therapy on long-term survival and late injury in patients with nasopharyngeal carcinoma after induction chemotherapy.

Safety and efficacy of low dose versus high dose corticosteroid for graft versus host disease (GVHD): A systematic review.
ascopubs.org

Longitudinal Costs of Image-Guided Intensity-Modulated Radiation Therapy Versus Three-Dimensional Conformal Radiation: Lessons From Phase III PARCER Trial for Shaping Resource ...

Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in ...